Translational Software Inc. Launches First FHIR-Based Pharmacogenomics API Allowing Healthcare Organizations And Software Developers To Quickly Scale And Accelerate Precision Medicine

BELLEVUE, Wash.--(BUSINESS WIRE)--Translational Software®, Inc., (TSI) a leader in the intelligent use of genetic data for clinical decision support and precision medicine, today announced the launch of a new Application Programming Interface (API) that enables health systems, labs and software developers to accelerate development of PGx-enhanced applications.

“We see a standardized API as a powerful means of simplifying this integration, and are grateful for the opportunity to collaborate with our partners to flesh out the standard.”

Developed using the Fast Healthcare Interoperability Resources (FHIR) specification, a new open-sourced standard for exchanging healthcare information to ensure interoperability, the API can be used to query TSI’s Knowledge-as-a-Service (KaaS) platform for drug-drug-gene intelligence to improve the prescription ordering process, alert clinicians to potential interactions and adverse drug events, and suggest medication alternatives.

“An important frontier of precision medicine is the use of clinical genomic data in routine patient care,” stated Gil Alterovitz, Ph.D., a Harvard Medical School professor in the Division of Medical Sciences, core faculty at the Computational Health Informatics Program in Boston Children’s Hospital and co-chair of HL7’s Clinical Genomics Work Group. “Translational Software has taken the pioneering step of implementing the first pharmacogenomics solution that employs FHIR genomics for optimizing the prescription of patient medications, and has been a real leader in this arena.”

The API is available for immediate use. Several leading organizations and independent software vendors are actively using the capability, including the Chan Soon-Shiong Institute of Molecular Research Institute, IT21 Solutions, First Vitals, RX Management, Sanford Health and Synergy Laboratories.

Initial efforts focused on developing FHIR apps that are integrated within the electronic health record to provide clinicians with alerts and reports regarding drug efficacy, dosing and potential adverse reactions at the point of care. The API will have increasing relevance to a broad range of health information systems and initiatives over time as genetic testing becomes routine to guide clinical decision making.

"One of the biggest impediments to wide-scale use of pharmacogenomics is the difficulty of integrating testing into the clinical workflow at the point where prescribing decisions are being made,” stated Don Rule, CEO, Translational Software. “We see a standardized API as a powerful means of simplifying this integration, and are grateful for the opportunity to collaborate with our partners to flesh out the standard.”

The API builds on TSI’s continued momentum in the market this year, including:

• Launch of a drug-drug interaction capability powered by First Databank to provide clinicians with a single source for drug-drug-gene intelligence;
• Continued growth in the hospital and health system market, securing new contracts with Inova Health System and Sanford Health;
• Expansion into global markets with new lab customers in Malaysia and South Africa;
• New product development initiatives, including a cystic fibrosis carrier screening panel that supports multiple genotyping platforms.

For more information on how to access the API and KaaS service platform, go to https://translationalsoftware.com/pharmacogenomics-api/.

About Translational Software, Inc.

Translational Software provides end-to-end solutions to support laboratories and healthcare providers adopting personalized medicine. Its powerful PGx portal transforms genomic and molecular data into actionable knowledge, integrating the best available clinical decision support with laboratory and clinical information systems to guide therapeutic options for medication management to enhance patient care. For more information visit www.translationalsoftware.com or follow us on LinkedIn.